NZ595602A - Anti-cancer drugs, and uses relating for malignant melanoma and other cancers - Google Patents

Anti-cancer drugs, and uses relating for malignant melanoma and other cancers

Info

Publication number
NZ595602A
NZ595602A NZ595602A NZ59560210A NZ595602A NZ 595602 A NZ595602 A NZ 595602A NZ 595602 A NZ595602 A NZ 595602A NZ 59560210 A NZ59560210 A NZ 59560210A NZ 595602 A NZ595602 A NZ 595602A
Authority
NZ
New Zealand
Prior art keywords
cancers
malignant melanoma
cancer drugs
uses relating
dimethylamino
Prior art date
Application number
NZ595602A
Other languages
English (en)
Inventor
Ganga Raju Gokaraju
Sudhakar Kasina
Rama Raju Gokaraju
Venkata Kanaka Ranga Raju Gokaraju
Venkateswarlu Somepalli
Trimurtulu Golakoti
Kiran Bhupathiraju
Krishanu Sengupta
Venkata Krishna Raju Alluri
Original Assignee
Kasina Laila Innova Pharmaceuticals Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kasina Laila Innova Pharmaceuticals Private Ltd filed Critical Kasina Laila Innova Pharmaceuticals Private Ltd
Publication of NZ595602A publication Critical patent/NZ595602A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D517/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains three hetero rings
    • C07D517/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ595602A 2009-04-27 2010-04-26 Anti-cancer drugs, and uses relating for malignant melanoma and other cancers NZ595602A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN959CH2009 2009-04-27
PCT/IN2010/000262 WO2010125575A1 (en) 2009-04-27 2010-04-26 Anti-cancer drugs, and uses relating for malignant melanoma and other cancers

Publications (1)

Publication Number Publication Date
NZ595602A true NZ595602A (en) 2013-05-31

Family

ID=42992332

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595602A NZ595602A (en) 2009-04-27 2010-04-26 Anti-cancer drugs, and uses relating for malignant melanoma and other cancers

Country Status (11)

Country Link
US (1) US8143237B2 (https=)
EP (1) EP2424351B1 (https=)
JP (1) JP5571168B2 (https=)
KR (1) KR20120006554A (https=)
CN (1) CN102438449B (https=)
AU (1) AU2010243213B2 (https=)
BR (1) BRPI1006651A2 (https=)
CA (1) CA2759519A1 (https=)
IL (1) IL215789A0 (https=)
NZ (1) NZ595602A (https=)
WO (1) WO2010125575A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101817221B1 (ko) 2010-11-18 2018-01-10 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 치환된 4-(셀레노펜-2(또는 3)-일아미노)피리미딘 화합물 및 이의 사용방법
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
CN103313599B (zh) * 2010-12-09 2016-03-23 卡斯纳莱拉创新药物私人有限公司 取代的4-(芳基氨基)硒吩并嘧啶化合物及其使用方法
WO2012176212A1 (en) 2011-06-20 2012-12-27 V.B. Medicare Pvt. Ltd. Carrier based nanogel formulation for skin targeting.
KR101418776B1 (ko) 2011-09-28 2014-07-14 사회복지법인 삼성생명공익재단 셀레노펜-접합 방향족 화합물, 및 이의 제조 방법
CN103906742A (zh) * 2011-09-28 2014-07-02 世宗大学校产学协力团 硒吩稠合芳族化合物和其制备方法
US8859781B2 (en) 2012-07-12 2014-10-14 Euclises Pharmaceuticals, Inc. No-releasing nonoate(nitrogen-bound)sulfonamide-linked-coxib anti-cancer agents
US9044464B2 (en) 2012-07-12 2015-06-02 Euclises Pharmaceuticals, Inc. No-releasing guanidine-coxib anti-cancer agents
WO2014018888A1 (en) 2012-07-26 2014-01-30 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as tak1 inhibitors in disease treatment
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
EP3247353A4 (en) 2015-01-23 2018-07-04 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer
CN108129475A (zh) * 2018-02-08 2018-06-08 中南大学湘雅三医院 一种生物光敏剂及其制备方法和应用
KR102648781B1 (ko) 2021-11-09 2024-03-19 국립공주대학교 산학협력단 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도
CN121712769A (zh) * 2023-06-29 2026-03-20 艾健科学股份有限公司 新型硒吩衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69724472T2 (de) * 1996-06-03 2004-06-17 Purdue Research Foundation, West Lafayette Selenophen-antitumormittel
US6620804B2 (en) * 1996-06-03 2003-09-16 Purdue Research Foundation Selenophene anti-tumor agents
WO2008016664A2 (en) * 2006-08-02 2008-02-07 University Of Massachusetts Lowell Compositions and methods for treating cancer with dacarbazine nanoemulsions
KR20110063537A (ko) * 2008-09-15 2011-06-10 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 전이성 악성 흑색종 및 기타 암에 대한 항암 약물 및 이와 관련한 용도

Also Published As

Publication number Publication date
HK1166591A1 (en) 2012-11-02
CN102438449B (zh) 2014-06-18
US20100272678A1 (en) 2010-10-28
BRPI1006651A2 (pt) 2015-08-25
AU2010243213B2 (en) 2014-09-11
CN102438449A (zh) 2012-05-02
JP5571168B2 (ja) 2014-08-13
WO2010125575A1 (en) 2010-11-04
IL215789A0 (en) 2012-01-31
AU2010243213A1 (en) 2011-10-27
CA2759519A1 (en) 2010-11-04
US8143237B2 (en) 2012-03-27
KR20120006554A (ko) 2012-01-18
JP2012525329A (ja) 2012-10-22
EP2424351B1 (en) 2015-10-21
EP2424351A1 (en) 2012-03-07
EP2424351A4 (en) 2013-04-03

Similar Documents

Publication Publication Date Title
NZ595602A (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
NZ577916A (en) Cyclopamine analogs
MX2014012695A (es) Derivados de isoindolona.
MY176944A (en) Substituted pyrimidines for the treatment of diseases such as cancer
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
GEP201706691B (en) Substituted phthalazin-1 (2h)-one derivatives as selecti- ve inhibitors of poly (adp-ribose) polymerase-1
TNSN08283A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
MX363609B (es) Bencimidazoles triciclicos sustituidos como inhibidores de cinasas.
TN2011000627A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
TN2010000071A1 (en) Fused imidazoles or cancer treatment
TW200714604A (en) Substituted heterocycles and the uses thereof
NZ594186A (en) Indole derivatives as anticancer agents
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
PH12012500497A1 (en) Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
AU2011274192A8 (en) Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
MX2012013274A (es) Novedosos derivados de la pirimidina.
MX2011007750A (es) Composiciones y metodos para inhibicion de la ruta jak.
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
MX2013010898A (es) Novedoso derivados de la pirimidina.
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
MY149716A (en) Pyridazine derivatives as smo inhibitors
MX2010005827A (es) Derivados de aminopirazol.
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MX2012004264A (es) Derivados de sulfoxidos para el tratamiento de tumores.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 APR 2023 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20140318

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 26 APR 2030 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20140318

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 APR 2020 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20140318

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 APR 2017 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20140318